GnRH agonists and superovulation for assisted conception

Infertility and Reproductive Medicine Clinics of North America

Volumn 12, Issue 1, 2001, Pages 89-104

  Balen, A ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUSERELIN; BUSERELIN ACETATE; CLOMIFENE CITRATE; FOLLITROPIN; GONADORELIN AGONIST; GOSERELIN; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN; LUTEINIZING HORMONE; NAFARELIN; NAFARELIN ACETATE; TRIPTORELIN;

CLINICAL PROTOCOL; CLINICAL TRIAL; COMORBIDITY; DESENSITIZATION; ECHOGRAPHY; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; FOLLICULAR PHASE; HUMAN; HYPOPHYSIS; INFERTILITY THERAPY; INTERMETHOD COMPARISON; LUTEAL PHASE; LUTEINIZING HORMONE RELEASE; OOCYTE DONATION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PATIENT MONITORING; PREDICTION; PREGNANCY RATE; REVIEW; SPONTANEOUS ABORTION; SUPEROVULATION;

EID: 0035191267     PISSN: 10479422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Comparative trial of luteinising hormonereleasing hormone analogue/HMG and clomiphene citrate/HMG in an assisted conception programme
2. Prospective study of short and long regimens of gonadotropin-releasing hormone agonist in in vitro fertilization program
3. Miscarriage rates following in vitro fertilisation are increased in women with polycystic ovaries and reduced by pituitary desensitisation with buserelin
4. Hypersecretion of luteinising hormone: A significant cause of infertility and miscarriage
5. The control of luteinising hormone secretion in the polycystic ovary syndrome
6. Comparison of ovarian stimulation regimens for in vitro fertilization (IVF) with and without a gonadotropin-releasing hormone (GnRH) agonist: Results of a randomized study
7. Randomized comparison of 2 long and short protocols of ovarian stimulation with LHRH-agonist for IVF including 342 cycles in 175 women
8. Requiem pour le protocol court?
9. Induction of ovulation in polycystic ovary syndrome with a combination of a luteinising hormone-releasing hormone analog and exogenous gonadotrophins
10. Comparison of short versus long-term leuprolide acetate-human menopausal gonadotrophin hyperstimulation in in vitro fertilization patients
11. Comparison of long-term versus three-day leuprolide acetate for ovarian stimulation in human in vitro fertilization program
12. Long versus short gonadotropin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles
13. Regulation of rat oocyte maturation: Involvement of protein kinases
14. Long acting versus daily administration GnRH analogs in IVF
15. A randomized prospective study on the effect of short and long buserelin treatment in women with repeated unsuccessful in vitro fertilization (IVF) cycles due to inadequate ovarian response
16. The ovarian androgen producing cells: A review of structure/function relationships
17. Inhibition systématique de l'hormone lutéinisante par un analogue de la gonadolibérine, la triptoréline, au cours de la stimulation ovarienne pour fécondation in vitro: Choix du protocole
18. Different gonadotropin and leuprorelin ovulation induction regimens markedly affect follicular fluid hormone levels and folliculogenesis
19. Successful treatment of infertile women with oligomenorrhoea using a combination of a luteinising hormone-releasing hormone agonist and exogenous gonadotrophins
20. The use of gonadotrophin-releasing hormone analogues in combination with exogenous gonadotropins in infertile women
21. Induction of multiple follicular development for in vitro fertilisation
22. Pregnancy outcome after exposure to gonadotropin releasing hormone analog during implantation
23. Etude randomisee entre protocole court et protocole long de busereline concernant 100 cycles de fecondation in vitro
24. Luteinising hormone-releasing hormone agonists in in vitro fertilisation: Different methods of utilization and comparison with previous ovulation stimulation treatments
25. Comparison between flare up and down regulation of luteinising hormone-releasing hormone agonists in an in vitro fertilisation programme
26. Premature ovulation during administration of human menopausal gonadotrophins in nonovulatory women
27. Outcome of pregnancies inadvertently exposed to GnRH-a in early gestation
28. Comparison of short 7-day and prolonged treatment with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation
29. Comparaison randomisee protocole long-protocole court dans les stimulations de l'ovaire en association avec un agoniste de la GnRH en vue de fecondation in vitro
30. Influence of serum luteinsing hormone concentrations on ovulation, conception and early pregnancy loss in polycystic ovary syndrome
31. Gonadotropin releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovaries
32. Effect of high tonic levels of luteinising hormone on outcome of in vitro fertilisation
33. Follicular development and early luteal function of conception and nonconception cycles after human in vitro fertilisation: Endocrine correlates
34. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: A meta-analysis of randomized trials
35. Profertility uses of luteinising hormone-releasing hormone agonist anologues
36. The influence development and management of functional ovarian zysts during IVF cycles
37. The routine use of gonadotrophin releasing hormone agonists for all patients undergoing in vitro fertilisation. Is there any medical advantage? A prospective randomised study
38. A randomized prospective study of early follicular or midluteal initiation of long protocol gonadotrophin releasing hormone in an IVF program
39. In vitro fertilisation and embryo transfer as related to endogenous luteinising hormone rise or human chorionic gonadotrophin administration
40. A prospective randomised single-blind comparative trial of nafarelin acetate with buserelin in long-protocol gonadotrophin releasing hormone analogue controlled IVF cycles
41. Hormonal changes induced by short-term administration of a gonadotropin-releasing hormone agonist during ovarian hyperstimulation for in vitro fertilization and their consequences for embryo development
42. Comparison of natural with clomiphene citrate-stimulated cycles in IVF: A prospective randomised trial
43. Short-term luteinising hormonereleasing hormone agonist treatment: Prospective trial of a novel ovarian stimulation regimen for in vitro fertilisation
44. Comparative trial between an ultra-short and long protocol of luteinizing hormone-releasing hormone agonist for ovarian stimulation in in vitro fertilization
45. Prospective randomized study of human menotropin versus a follicular and a luteal phase gonadotropin-releasing hormone analog-human menotropin stimulation protocols for in vitro fertilization
46. Relationships between the characteristics of endogenous luteinising hormone surge and the degree of ovarian hyperstimulation during superovulation induction in women
47. The Lupron screening test: Tailoring the use of leuprolide acetate in ovarian stimulation for in vitro fertilization
48. Nafarelin versus leuprolide in ovulation induction for IVF: A randomised clinical trial
49. Ovarian response and outcome of in vitro fertilization in patients treated with gonadotrophin-releasing hormone analogues in different phases of the menstrual cycle
50. Polycystic ovaries: A common finding in normal women
51. Induction of ovulation for in vitro fertilisation using buserelin and gonadotrophins
52. Spontaneous luteinising hormone surge and cleavage of in vitro fertilised embryos
53. Hypersecretion of luteinising hormone, infertility and miscarriage
54. The duration of pituitary suppression by means of intranasal gonadotropin hormone-releasing hormone analogue administration does not influence the ovarian response to gonadotropin stimulation and success rate in a gamete intrafallopian transfer (GIFT) program
55. The comparison of early follicular and midluteal administration of long-acting gonadotrophin releasing hormone agonist
56. Improvement of in vitro fertilisation after treatment with buserelin, an agonist of luteinising hormone-releasing hormone
57. Comparison between long and short protocols of luteinising hormone-releasing hormone agonist in the treatment of PCOD by in vitro fertilisation
58. A prospective randomized comparison of luteal phase versus concurrent follicular phase initiation of gonadotropin-releasing hormone agonist for in vitro fertilization
59. Increased pregnancy failure rates after clomiphene following assisted reproductive technology
60. Hormonal profiles following clomiphene citrate therapy in conception and nonconception cycles
61. Incidence of severe ovarian hyperstimulation syndrome after gonadotrophin releasing hormone agonist/HMG superovulation for in vitro fertilisation
62. Infusion of gonadotropin-releasing hormone agonist during pregnancy: Maternal and fetal responses in primates
63. Reduced in vitro fertilisation of human oocyte from patients with raised basal luteinising hormone levels during the follicular phase
64. A controlled ovarian hyperstimulation regimen involving intermittent gonadotropin administration with a "short" protocol of gonadotropin releasing hormone agonist for in vitro fertilization
65. A controlled ovarian hyperstimulation regimen involving intermittent gonadotropin administration with a "short" protocol of gonadotropin releasing hormone agonist for in vitro fertilization
66. The long protocol of administration of gonadotrophin-releasing hormone agonist is superior to the short protocol for ovarian stimulation for in vitro fertilisation
67. A prospective randomised study of the optimum timing of human chorionic gonadotrophin administration after pituitary desensitisation in in vitro fertilisation
68. Cumulative conception and livebirth rates after IVF, with and without, pituitary desensitization with the gonadotropin-releasing hormone agonist, buserelin
69. Comparison between nafaraelin acetate and D-Trp6-LHRH for temporary pituitary suppression in IVF patients: A prospective crossover study
70. Follicle cyst formation after administration of different gonadotrophin-releasing hormone analogues for assisted reproduction
71. Is long-protocol gonadotropin releasing hormone agonist administration superior to the short protocol in ovarian stimulation for in vitro fertilization?
72. Do raised serum luteinising hormone levels during stimulation for in vitro fertilisation predict outcome?
73. Midluteal buserelin is superior to early follicular phase buserelin in combined gonadotrophin releasing hormone analog and gonadotropin stimulation in IVF
74. Clinical aspects with regard to the occurrence of an endogenous luteinising hormone surge in gonadotrophin-induced normal menstrual cycles
75. The evaluation of a new 7-day gonadotropin-releasing hormone agonist protocol in the controlled ovarian hyperstimulation for in vitro fertilization
76. Comparison of short versus long protocol of LHRHa-HMG stimulation in IVF